Fig. 6

Transcriptional profiling of HRD in single cell-sequenced breast cancer cells. a Correlation of mean HRD transcriptional score across individual cancer cells against matched bulk RNA sequencing from the Chung et al. cohort (47). b Distribution of HRD scores across tumour cells from a Stage III BRCA1-defective TNBC sample (sc5rJUQ033) and a Stage II Luminal A sample (sc5rJUQ064) from the Qian et al. cohort (48). c–e Profiling of HRD across tumour cells from the Qian et al. cohort as demonstrated by UMAP coordinates labelled by c HRD score and d breast cancer subtype. e The proportion of cells within each sample with HRD scores greater than zero in the Qian et al. cohort. The defined breast cancer subtypes include here are: ‘B1 TN’ = BRCA1-defective Triple negative, ‘Lum HER2’ = Luminal-HER2+ , ‘HER2’ = HER2 positive, ‘TN’ = Triple negative, ‘LumA’ = Luminal A-like, ‘LumB’ = Luminal B-like. f–h Profiling of HRD across tumour cells from the Bassez et al. cohort (49), similar to c–e